HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tomokazu Oyama Selected Research

Metabolic Syndrome (Dysmetabolic Syndrome X)

4/2007Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tomokazu Oyama Research Topics

Disease

14Type 2 Diabetes Mellitus (MODY)
01/2011 - 01/2004
6Insulin Resistance
06/2010 - 09/2004
4Obesity
03/2013 - 09/2004
4Body Weight (Weight, Body)
05/2009 - 09/2004
3Atherosclerosis
10/2010 - 04/2008
3Hypertension (High Blood Pressure)
10/2009 - 12/2006
3Hypercholesterolemia
10/2008 - 01/2004
3Diabetes Mellitus
04/2008 - 06/2006
2Albuminuria
01/2013 - 02/2006
2Diabetic Nephropathies (Diabetic Nephropathy)
01/2013 - 02/2006
2Hyperglycemia
01/2011 - 09/2006
1Weight Loss (Weight Reduction)
03/2013
1Heart Failure
01/2013
1Pancreatic Neoplasms (Pancreatic Cancer)
10/2008
1Obstructive Jaundice (Cholestatic Jaundice)
10/2008
1Coronary Artery Disease (Coronary Atherosclerosis)
10/2007
1Metabolic Syndrome (Dysmetabolic Syndrome X)
04/2007
1Cardiovascular Diseases (Cardiovascular Disease)
04/2007
1Arteriosclerosis
06/2006

Drug/Important Bio-Agent (IBA)

8Lipoprotein Lipase (Diacylglycerol Lipase)IBA
06/2010 - 01/2004
5Glucose (Dextrose)FDA LinkGeneric
10/2007 - 09/2004
3Probucol (Lorelco)FDA Link
01/2013 - 02/2006
3oxidized low density lipoproteinIBA
10/2010 - 06/2006
3Angiotensin Receptor AntagonistsIBA
10/2009 - 06/2006
2AlbuminsIBA
01/2013 - 02/2006
2Insulin (Novolin)FDA Link
01/2011 - 04/2006
2CholesterolIBA
10/2010 - 10/2008
2Angiotensin IIIBA
06/2010 - 05/2009
2Amlodipine (Norvasc)FDA LinkGeneric
10/2009 - 10/2009
2CarbohydratesIBA
10/2007 - 09/2004
2AdiponectinIBA
10/2007 - 04/2007
28-Hydroxy-2'-DeoxyguanosineIBA
09/2006 - 02/2006
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
02/2006 - 01/2004
2Atorvastatin (Lipitor)FDA Link
02/2006 - 01/2004
1CreatinineIBA
01/2013
1Brain Natriuretic Peptide (Natrecor)FDA Link
01/2013
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
01/2011
1insulin aspart protamine drug combination 30:70 insulin aspartIBA
01/2011
1Biphasic InsulinsIBA
01/2011
1Ezetimibe (Zetia)FDA Link
10/2010
1LDL CholesterolIBA
10/2010
1Pioglitazone (Actos)FDA Link
06/2010
1Calcium Channel Blockers (Blockers, Calcium Channel)IBA
10/2009
1L-Type Calcium Channels (Dihydropyridine Receptor)IBA
10/2009
1Angiotensin Receptors (Angiotensin II Receptor)IBA
10/2009
1Calcium Channels (Calcium Channel)IBA
10/2009
1olmesartanIBA
10/2009
1pitavastatin (itavastatin)FDA Link
10/2009
1efonidipineIBA
10/2009
1LDL Lipoproteins (beta Lipoproteins)IBA
10/2009
1LeptinIBA
05/2009
1Hemoglobin AIBA
05/2009
1Apolipoproteins B (ApoB)IBA
10/2008
1Lipoproteins (Lipoprotein)IBA
10/2008
1Glycoside Hydrolase InhibitorsIBA
06/2008
1AcarboseFDA LinkGeneric
06/2008
17-ketocholesterolIBA
04/2008
1OxysterolsIBA
04/2008
1Metformin (Glucophage)FDA LinkGeneric
10/2007
1HDL CholesterolIBA
04/2007
1Triglycerides (Triacylglycerol)IBA
04/2007
1Biomarkers (Surrogate Marker)IBA
04/2007
1Valsartan (Vals)FDA Link
12/2006
1Caspase 3 (Caspase-3)IBA
09/2006
1benidipine hydrochlorideIBA
06/2006
1CalciumIBA
06/2006
1candesartan cilexetil (Amias)FDA Link
06/2006
1Isophane Insulin (NPH Insulin)FDA Link
04/2006
1Proteins (Proteins, Gene)FDA Link
09/2004
1Pravastatin (Pravachol)FDA LinkGeneric
01/2004
1Coenzyme A (CoA)IBA
01/2004
1Oxidoreductases (Dehydrogenase)IBA
01/2004
1Heparin (Liquaemin)FDA LinkGeneric
01/2004

Therapy/Procedure

5Therapeutics
03/2013 - 04/2006
1Aftercare (After-Treatment)
01/2013
1Renal Dialysis (Hemodialysis)
01/2013
1Reducing Diet
05/2009
1Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
09/2004
1Caloric Restriction
09/2004